DADC
SAGE

D.A. Davidson & Co’s Sage Therapeutics SAGE Stock Holding History

D.A. Davidson & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,536
Closed -$217K – 1156
2018
Q3 		$217K Sell
1,536
-34
-2% -$5.25K ﹤0.01% 1050
2018
Q2 		$246K Sell
1,570
-153
-9% -$24K ﹤0.01% 948
2018
Q1 		$278K Hold
1,723
– – 0.01% 886
2017
Q4 		$284K Buy
+1,723
New +$167K 0.01% 871
2017
Q3 		– Sell
-767
Closed -$61K – 1817
2017
Q2 		$61K Sell
767
-50
-6% -$3.62K ﹤0.01% 1462
2017
Q1 		$58K Sell
817
-134
-14% -$7.85K ﹤0.01% 1465
2016
Q4 		$47K Buy
+951
New +$44.8K ﹤0.01% 1615

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

D.A. Davidson & Co's SAGE Position: Q4 2018 in Review

D.A. Davidson & Co sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 1,536 shares — an estimated $217K sold.

D.A. Davidson & Co first reported a position in SAGE in Q4 2016 and held it in 7 quarters. The position peaked at $284K in Q4 2017. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

  • D.A. Davidson & Co reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
  • D.A. Davidson & Co sold 1,536 Sage Therapeutics shares in Q4 2018, an estimated $217K.
  • D.A. Davidson & Co first reported a position in Sage Therapeutics in Q4 2016 and held it in 7 quarters.
  • D.A. Davidson & Co's Sage Therapeutics position peaked at $284K in Q4 2017.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on D.A. Davidson & Co's 13F filing for Q4 2018, filed 29 Jan 2019.